Novel therapy for myocardial infarction: can HGF/Met be beneficial?

Cell Mol Life Sci. 2011 May;68(10):1703-17. doi: 10.1007/s00018-011-0633-6. Epub 2011 Feb 17.

Abstract

Myocardial infarction (MI) is a leading cause of hospitalization worldwide. A recently developed strategy to improve the management of MI is based on the use of growth factors which are able to enhance the intrinsic capacity of the heart to repair itself or regenerate after damage. Among others, hepatocyte growth factor (HGF) has been proposed as a modulator of cardiac repair of damage due to the pleiotropic effects elicited by Met receptor stimulation. In this review we describe the mechanistic basis for autocrine and paracrine protection of HGF in the injured heart. We also analyse the role of HGF/Met in stem cell maintenance and in stem cell therapies for MI. Finally, we summarize the most significant results on the use of HGF in experimental models of heart injury and discuss the potential of the molecule for treating ischaemic heart disease in humans.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Genetic Therapy
  • Hepatocyte Growth Factor / genetics
  • Hepatocyte Growth Factor / physiology*
  • Hepatocyte Growth Factor / therapeutic use
  • Humans
  • Myocardial Infarction / physiopathology
  • Myocardial Infarction / therapy*
  • Paracrine Communication
  • Proto-Oncogene Proteins c-met / genetics
  • Proto-Oncogene Proteins c-met / metabolism
  • Proto-Oncogene Proteins c-met / physiology*
  • Receptors, Growth Factor / genetics
  • Receptors, Growth Factor / metabolism
  • Receptors, Growth Factor / physiology*
  • Stem Cells / cytology
  • Stem Cells / metabolism

Substances

  • Receptors, Growth Factor
  • Hepatocyte Growth Factor
  • MET protein, human
  • Proto-Oncogene Proteins c-met